Fig 16. Therapeutic dosing of Compound A protected mice from bleomycin-induced pulmonary fibrosis.

For the therapeutic arm of this experiment, the cohorts were (1) i.t.-delivered saline control group (n = 5 mice), (2) bleomycin-instilled no treatment group (n = 5), (3) bleomycin-treated vehicle control cohort (n = 12), (4) bleomycin-instilled Compound A treated (10 mg/kg) group (n = 12), (5) bleomycin-instilled pirfenidone treated (10 mg/kg) cohort (n = 12), and (6) bleomycin-instilled group with dexamethasone (3 mg/kg delivered i.p.) administered every other day (n = 12). Treatment for mice that received bleomycin started on day 6 and continued to day 13. As with the prophylactic study, mice were scored for fibrosis (A), collagen deposition (B) and the soluble lung collagen content (C). The mean scores ± SEM are shown.